S
Stefanie Zorbas-Seifried
Researcher at Max Planck Society
Publications - 6
Citations - 1753
Stefanie Zorbas-Seifried is an academic researcher from Max Planck Society. The author has contributed to research in topics: NAMI-A & Cancer. The author has an hindex of 6, co-authored 6 publications receiving 1600 citations.
Papers
More filters
Journal ArticleDOI
From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
Christian G. Hartinger,Stefanie Zorbas-Seifried,Michael A. Jakupec,Bernd Kynast,Haralabos Zorbas,Bernhard K. Keppler +5 more
TL;DR: The preclinical and early clinical development of KP1019 - from bench to bedside - is recapitulated and promising activity against certain types of tumors is observed.
Journal ArticleDOI
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.
Christian G. Hartinger,Christian G. Hartinger,Michael A. Jakupec,Stefanie Zorbas-Seifried,Michael Groessl,Alexander E. Egger,Walter Berger,Haralabos Zorbas,Paul J. Dyson,Bernhard K. Keppler +9 more
TL;DR: The experimental evidence for the proposed mode of action of this coordination compound is discussed, including transport into the cell via the transferrin cycle and activation by reduction.
Journal ArticleDOI
KP1019, A New Redox-Active Anticancer Agent — Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
Christian G. Hartinger,Christian G. Hartinger,Michael A. Jakupec,Stefanie Zorbas-Seifried,Michael Groessl,Alexander E. Egger,Walter Berger,Haralabos Zorbas,Paul J. Dyson,Bernhard K. Keppler +9 more
TL;DR: The promising drug candidate indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) is the second Ru-based anticancer agent to enter clinical trials as mentioned in this paper.
Journal ArticleDOI
Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands.
Stefanie Zorbas-Seifried,Michael A. Jakupec,Nikolay V. Kukushkin,Michael Groessl,Christian G. Hartinger,Olga Semenova,Haralabos Zorbas,Vadim Yu. Kukushkin,Bernhard K. Keppler +8 more
TL;DR: The presence of cis-configured exchangeable ligands has long been considered a prerequisite for antitumor activity of platinum complexes, but over the past few years, several examples violating this structure-activity relationship have been recognized as mentioned in this paper.
Journal ArticleDOI
The first ruthenium-based paullones: syntheses, X-ray diffraction structures, and spectroscopic and antiproliferative properties in vitro.
Wolfgang F. Schmid,Stefanie Zorbas-Seifried,Roland O. John,Vladimir B. Arion,Michael A. Jakupec,Alexander Roller,Markus Galanski,Ion Chiorescu,Haralabos Zorbas,Bernhard K. Keppler +9 more
TL;DR: The novel paullone derivatives exhibit remarkable antiproliferative activity in three human carcinoma cell lines, A549 (non-small cell lung carcinoma), CH1 (ovarian carcinoma, and SW480 (colon carcinoma).